Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UMLS:C0018681 (headache)
 56,091 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

The therapeutic effect of tiapride was studied in 54 patients attending a neurological department for various types of headaches. In most cases these had been present for several years and were resistant to treatment. The average dosage of tiapride was one tablet three times per day. The headache had completely disappeared after treatment in 17 patients. In 28 patients they reappeared after discontinuing treatment but disappeared again when tiapride was again administered. The symptom persisted in 9 patients. Best results were obtained in post-traumatic and psychogenic headaches and in migraine. Results were less successful in headaches occurring in epileptic patients. Tolerance was good and no significant extrapyramidal, neurovegetative, or neuro-endocrine effects were observed.
 ...
PMID:[Treatment of headache with tiapride (author's transl)]. 625 55

A preliminary open study was conducted in 20 women with menopausal sudden flushes to assess the effect of veralipride, administered as 100 mg/day for 20 days. In 15 cases, sudden flushes and night sweats were no longer present following treatment and behaviour had considerably improved. In the remaining 5 cases, sudden flushes were reduced in number and severity. A second study was then conducted in 40 women with the same symptoms, to compare the efficacy of veralipride and placebo under double-blind conditions. Successful results were obtained in 15 patients after veralipride and 5 after placebo, while treatment was a failure in 5 patients after veralipride and 15 after placebo. The difference is very significant in favor of veralipride (p < 0,01). Best results were obtained on sudden flushes, followed by mood and behavior disorders, with less consistent results in headache, pruritus vulvae, and palpitations. Clinical tolerance was good as only 4 cases of difficulty in falling asleep, 3 cases of mammary tension, and 2 cases of dryness of the mouth were reported. Biological parameters and vaginal smears were not modified by treatment.
 ...
PMID:[Clinical study of the action of a new molecule, veralipride, on menopausal psychofunctional disorders (author's transl)]. 625 63

The symptomatology of the premenstrual syndrome is frequently seen in general and gynecological practice. The aim of this study was to examine the therapeutical effect of dydrogesterone (Duphaston) on the typical premenstrual complaints as depression, headache, edema, mastodynia, dysmenorrhea and bleeding irregularities. Oral administration of 20 mg dydrogesterone b.i.d. during the second half of the menstrual cycle could well relieve the complaints mentioned above. Best results of treatment were obtained in cases of dysmenorrhea, bleeding irregularities, depression and edema. In our patients mastodynia was not influenced by dydrogesterone-therapy. As shown by basal body temperature and progesterone in plasma the menstrual cycles remained ovulatory under therapy. The treatment with dydrogesterone was tolerated well in general, blood pressure and body weight were not altered significantly. The majority of patients wished to continue the treatment beyond the period of this study.
 ...
PMID:[Treatment of the premenstrual syndrome with a retroprogesterone (Duphaston)]. 718 74

A practical application of a neurology case management healthcare delivery mode results in increased access to specialty providers, shorter follow-up periods, and improved continuity of medical care. The program described in the following sections was developed at a naval hospital for the ongoing evaluation of therapeutic schemes to optimize headache therapy and, 1 year after implementation, shows improvement in patient outcomes and resource use.
Best Pract Benchmarking Healthc
PMID:Critical path case management: the headache clinic. 919 70

The paper is devoted to review literature data on intravenous and oral antiemetic effectivity of granisetron (GRAN) a selective 5HT3 antagonist and to determine the optimal dose for the prophylaxis of chemotherapy-induced acute emesis. The drug was put on the market in the injectable form in 1994 and in the oral form in 1995, so a sufficient number of reports have been published for the evaluation. According to the summarized data on 6095 patients treated with intravenous GRAN, on average 66% antiemetic complete response (CR) rate was reached (i.e. no vomiting in the first 24 hours of chemotherapy). Best results were observed with the dose of 40 microg/kg intravenous GRAN, on average 70% CR (range 47-93%) were achieved in 4182 of the 6095 patients with this dose. In 942 patients treated with the mostly applied oral dose of GRAN (1 mg twice daily), on average 61% CR (range 52-82%) were reported. Side effects were weak and transient, mostly headache and constipation were observed. Headache appeared in 13% with the use of 40 microg/kg intravenous dose GRAN and in 18% with 1 mg oral dose twice daily Constipation was observed in 5.3% and 17% with the injection and oral dose, respectively.
 ...
PMID:About the antiemetic effectivity of granisetron in chemotherapy-induced acute emesis: a comparison of results with intravenous and oral dosing. 1046 29

Multimodal pain management programmes have been used for chronic pain conditions such as low back pain or headache for many years with good results. However their effectiveness for treating fibromyalgia has only recently been established and with respect to long-term outcome the evidence is still not convincing. Recent findings, about abnormalities in pain control and neuroendocrine systems, help to understand the symptomatology of fibromyalgia and give theoretical support for these treatment concepts. They might also explain why secondary phenomena like depression, anxiety, deconditioning and disability can make it harder to treat the condition at a chronic stage. The ingredients of such multimodal programmes are described and evidence for their effectiveness is presented.
Baillieres Best Pract Res Clin Rheumatol 1999 Sep
PMID:Pain management strategies and team approach. 1056 81

Pituitary tumours are normally benign, highly differentiated and slow growing neoplasms. Nevertheless, as many as half of them will show evidence of local invasion into the surrounding structures. Despite their benign growth characteristics and slow clinical progression, pituitary tumours commonly cause serious morbidity. The mass effects of large tumours, including headache and visual failure from optic chiasm compression, may cause lifelong disability. Hormone hypersecretion or deficiency causes major clinical problems that often require expensive and long-term medical therapy. Major advances have been made in the therapy of pituitary tumours over the past 20-30 years, but despite this, their treatment often remains an unsatisfactory compromise in practice. There is, therefore, a place for improvements in therapy, and to this end, gene therapy may come to hold a significant place in the future treatment of human pituitary tumours. With the development of new gene delivery vehicles, this concept can now be explored with a view to treating specific types of pituitary tumours.
Baillieres Best Pract Res Clin Endocrinol Metab 1999 Oct
PMID:Recent developments in gene therapy: applications for the treatment of pituitary tumours. 1090 34

Although levonorgestrel contraceptive implants have been available for over 15 years, innovations have only recently led to a wider choice. These new implants offer easier insertion and removal and other advantages depending on the type of progestin. Implants prevent pregnancy by several mechanisms, including inhibition of ovulation and luteal function and alteration of cervical mucus and the endometrium. The high efficacy and ease of maintenance make implants an ideal contraceptive for many women, including adolescents, a population that uses implants infrequently but reports high satisfaction. Implants are appropriate for women who are breastfeeding, who have contraindications to estrogen, or who have diseases such as diabetes, hypertension, sickle cell anemia, or an HIV infection because implants have few metabolic or hematologic effects. Long-term use has not been associated with a decrease in BMD and generally leads to increased blood levels and iron stores. Women who wish to space their pregnancies appreciate the nearly immediate onset of action with insertion and the rapid termination of all effects with removal. All types of implants lead to menstrual changes and other side effects in some women. Adverse effects that occur in implant users more than the general population include headaches and acne. Women must be thoroughly counseled regarding the potential for menstrual alteration, side effects, and sexually transmitted infections if they do not use condoms. Despite their initial high cost, implants are a cost-effective method over several years, even when discontinued before the life of the implant.
 ...
PMID:Implantable contraception. 1109 88

Low back pain (LBP) poses an economic burden to society, mainly in terms of the large number of work days lost by a small percentage of patients who develop chronic LBP. The object of this review is to gain a better understanding of the societal costs of LBP and to see whether current clinical management follows evidence-based guidelines and is economically attractive, by reviewing studies on LBP with economic implications. To this end, the Medline database was searched between 1996 and 2001 using appropriate keywords, broadly defined. A total of 372 abstracts were screened and paper copies of 73 potentially relevant articles were obtained. It was found that the cost of LBP illness was high and was comparable to other disorders such as headache, heart disease, depression or diabetes, but actual cost estimates varied depending on the costing methodology employed. A small percentage of patients with chronic LBP accounts for a large fraction of the costs. Excessive and inappropriate use of diagnostic or therapeutic services can be documented but varied by region and provider type. Management according to evidence-based guidelines was not necessarily economically attractive. Interventions for acute or chronic LBP failed to show economic benefits, but demonstrated modest clinical benefits, which suggested a weak relationship between clinical and economic outcomes. The conclusion was that common definitions and costing methodologies need to be found to gain a better understanding of the true costs to society and to make studies comparable. A better definition is needed for the type for patient with LBP for whom therapeutic management is most likely to have a long-lasting economic benefit.
Best Pract Res Clin Rheumatol 2002 Jan
PMID:The economic burden of low back pain: a review of studies published between 1996 and 2001. 1198 29

Spinal anaesthesia in the outpatient is characterized by rapid onset and offset, easy administration, minimal expense, and minimal side effects or complications. Spinal anaesthesia offers advantages for outpatient lower extremity, perineal, and many abdominal and gynaecological procedures. Development of small-gauge, pencil-point needles are responsible for the success of outpatient spinal anaesthesia with acceptable rates (0-2%) of postdural puncture headache (PDPH). Compared with peripheral nerve blocks, spinal anaesthesia has a more predictable offset. There are many possible choices of local anaesthetics for outpatient spinal anaesthesia. These include lidocaine, prilocaine, mepivacaine and small doses of bupivacaine. Meperidine has local anaesthetic properties in addition to its opiate properties. It has been used as the sole intrathecal agent for spinal anaesthesia but has no real advantages over lidocaine. Mepivacaine and lidocaine have each been associated with transient neurological symptoms (TNS) following intrathecal administration. This has stimulated development of alternative agents, including combinations of local anaesthetics and opioids. Lidocaine remains the most useful agent for outpatient spinal anaesthesia. For longer procedures, mepivacaine is an excellent spinal anaesthetic agent. Attention to technique, reduction of dose and addition of fentanyl to lidocaine result in effective spinal anaesthesia with rapid recovery and a low incidence of significant side effects or complications.
Best Pract Res Clin Anaesthesiol 2003 Sep
PMID:Spinal anaesthesia for outpatient surgery. 1452 6


1 2 3 4 Next >>